The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Wake Forest University Health Sciences
UMC Utrecht
Boehringer Ingelheim
Aktis Oncology, Inc.
University of California, Irvine
ViroMissile, Inc.
AstraZeneca
Washington University School of Medicine
AstraZeneca
Tizona Therapeutics, Inc
ALX Oncology Inc.
Betta Pharmaceuticals Co., Ltd.
University of Colorado, Denver
Karolinska University Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Daiichi Sankyo
Oscotec Inc.
Kidney Cancer Research Bureau
Adela, Inc
Perspective Therapeutics
Elephas
Elephas
UNICANCER
VM Oncology, LLC
Pfizer
Memorial Sloan Kettering Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
LigaChem Biosciences, Inc.
University of Colorado, Denver
British Columbia Cancer Agency
Washington University School of Medicine
Institut Claudius Regaud
Memgen, Inc.
Abramson Cancer Center at Penn Medicine
The Netherlands Cancer Institute
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Stanford University
University of California, Irvine
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
Rapa Therapeutics LLC
Columbia University
Nanjing First Hospital, Nanjing Medical University
University Health Network, Toronto
Centre Hospitalier Universitaire de Besancon
Pack Health
University Health Network, Toronto
Fondazione Policlinico Universitario Agostino Gemelli IRCCS